Adverse human health effects associated with molds in the indoor environment

Journal of Occupational and Environmental Medicine

Volumn 45, Issue 5, 2003, Pages 470-478

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

MYCOTOXIN;

ALLERGY; ARTICLE; ASTHMA; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; FUNGUS GROWTH; HEALTH HAZARD; HUMAN; INDOOR AIR POLLUTION; INGESTION; INHALATION; MOULD; MYCOSIS; MYCOTOXICOSIS; OCCUPATIONAL EXPOSURE; RHINITIS; SINUSITIS;

AJELLOMYCES; ANIMALIA; BLASTOMYCES; COCCIDIOIDES; FUNGI; STACHYBOTRYS CHARTARUM;

EID: 0038627911     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-200305000-00006     Document Type: Article

References (83)

1. Solomon WR, Platts-Mills TAE. Aerobiology and Inhalant Allergens. In: Middleton E, Jr et al, eds. Allergy: Principles and Practice. St. Louis: Mosby Co.; 1998:367-403.
2. Horner WE, Helbling A, Salvaggio JE, Lehrer SB. Fungal allergens. Clin Microbiol Rev. 1995;8:161-179.
3. Billings CG, Howard P. Damp housing and asthma. Monaldi Arch Chest Dis. 1998;53:43-49.
4. Burr ML. Health effects of indoor molds. Rev Environ Health. 2001;16:97-103.
5. Macher J. Health effects of bioaerosols. In: Macher J, ed. Bioaerosols: Assessment and Control. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, 1999:3-1 to -12.
6. Purokivi MK, Hirvonen MR, Randell JT, et al. Changes in pro-inflammatory cytokines in association with exposure to moisture-damaged building microbes. Eur Respir J. 2001;18:951-958.
7. Roponen M, Seuri M, Nevalainen A, Hirvonen MR. Fungal spores as such do not cause nasal inflammation in mold exposure. Inhal Toxicol. 2002;14:541-549.
8. Fink J, Zacharisen MC. Hypersensitivity Pneumonitis. In: Middleton E Jr., et al, eds. Allergy: Principles and Practice. St. Louis: Mosby Co.; 1998:994-1004.
9. Flaherty DK, Barboriak J, Emanuel D, et al. Multilaboratory comparison of three immunodiffusion methods used for the detection of precipitating antibodies in hypersensitivity pneumonitis. J Lab Clin Med. 1974;84:298-306.
10. California Department of Health Services, Environmental Health Investigations Branch: Misinterpretatin of Stachybotrys serology, 2000. www. dhs. ca.gov/ps/deodc/ehib/ehib2/topics/serologyf2. htm, accessed 2002.
11. Greenberger PA. Allergic bronchopulmonary aspergillosis, allergic fungal sinusitis, and hypersensitivity pneumonitis. Clin Allergy Immunol. 2002;16:449-468.
12. Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy. 1986;56:444-448.
13. Cockrill BA, Hales CA. Allergic bronchopulmonary aspergillosis. Annu Rev Med. 1999;50:303-316.
14. Zhaoming W, Lockey RF. A review of allergic bronchopulmonary aspergillosis. J Invest Allergol Clin Immunol. 1996;6:144-151.
15. Slavin RG. Allergic bronchopulmonary aspergillosis. Clin Rev Allergy. 1985;3:167-182.
16. Katzenstein AL, Sale SR, Greenberger PA. Allergic Aspergillus sinusitis: a newly recognized form of sinusitis. J Allergy Clin Immunol. 1983;72:89-93.
17. deShazo RD, Swain RE. Diagnostic criteria for allergic fungal sinusitis. J Allergy Clin Immunol. 1995;96:24-35.
18. Schubert MS, Goetz DW. Evaluation and treatment of allergic fungal sinusitis. I. Demographics and diagnosis. J Allergy Clin Immunol. 1998;102:387-394.
19. Schubert MS. Fungal rhinosinusitis: diagnosis and therapy, Curr Allergy Asthma Rep. 2001;1:268-276.
20. Blonz ER. Is there an epidemic of chronic candidiasis in our midst? JAMA. 1986;256:3138-3139.
21. Executive Committee of the American Academy of Allergy and Immunology. Clinical ecology. J Allergy Clin Immunol. 1986;78:269-271.
22. Hawkins C, Armstrong D. Fungal infections in the immunocompromised host. Clin Haematol. 1984;13:599-630.
23. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol. 1989;5:131-142.
24. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001;33:1692-1696.
25. Munoz P, Burillo A, Bouza E. Environmental surveillance and other control measures in the prevention of nosocomial fungal infections. Clin Microbiol Infect. 2001;7(Suppl 2):38-45.
26. Ciegler A, Burmeister HR, Vesonder RF, Hesseltine CW. Mycotoxins: occurrence in the environment. In: Shank RC, ed. Mycotoxins and N-nitroso Compounds: Environmental Risks. Volume I. Boca Raton, FL: CRC Press, Inc.; 1981:1-50.
27. Committee on Protection Against Mycotoxins. National Research Council. Protection Against Trichothecene Mycotoxins. Washington, DC: National Academy Press; 1983.
28. Hendry KM, Cole EC. A review of mycotoxins in indoor air. J Toxicol Environ Health. 1993;38:183-198.
29. Nikulin M, Pasanen AL, Berg S, Hintikka EL. Stachybotrys atra growth and toxin production in some building materials and fodder under different relative humidities. Appl Environ Microbiol. 1994;60:3421-3424.
30. Rao CY. Toxigenic fungi in the indoor environment. In: Spengler JD, Samset JM, McCarthy JS, eds. Indoor Air Quality Handbook. New York: McGraw Hill; 2001:46-2 and 46-4.
31. Nikulin M, Reijula K, Jarvis BB, Hintikka EL. Experimental lung mycotoxicosis in mice induced by Stachybotrys atra. Int J Exp Pathol. 1996;77:213-218.
32. Jarvis BB, Sorenson WG, Hintikka EL, et al. Study of toxin production by isolates of Stachybotrys chartarum and Memnoniella echinata isolated during a study of pulmonary hemosiderosis in infants. Appl Environ Microbiol. 1998;64:3620-3625.
33. Vesper SJ, Dearborn DG, Yike I, Sorenson WG, Haugland RA. Hemolysis, toxicity, and randomly amplified polymorphic DNA analysis of Stachybotrys chartarum strains. Appl Environ Microbiol. 1999;65:3175-3181.
34. Andersen B, Nielsen KF, Jarvis BB. Characterization of Stachybotrys from water-damaged buildings based on morphology, growth, and metabolic production. Mycologia. 2002;943:392-403.
35. Tobin RS, Baranowski E, Gilman AP, Kuiper-Goodman T, Miller JD, Giddings M. Significance of fungi in indoor air: report of a working group. Can J Public Health. 1987;78:S1-S32.
36. Smith JE, Anderson JG, Lewis CW, Murad YM. Cytotoxic fungal spores in the indoor atmosphere of the damp domestic environment. FEMS Microbiol Lett. 1992;79:337-343.
37. Rao CY, Burge HA, Chang JC. Review of quantitative standards and guidelines for fungi in indoor air. J Air Waste Manag Assoc. 1996;46:899-908.
38. Tuomi T, Reijula K, Johnsson T, et al. Mycotoxins in crude building materials from water-damaged buildings. Appl Environ Microbiol. 2000;66:1899-1904.
39. Schiefer HB. Mycotoxins in indoor air: a critical toxicological viewpoint. Indoor air '90: Proceedings of the Fifth International Conference on Indoor Air, 1990;167-172.
40. World Health Organization. Selected mycotoxins: ochratoxins, trichothecenes, ergot. In: Environmental Health Criteria 105. Geneva: WHO; 1990;30, 77, 169.
41. Drobotko VG. Stachybotryotoxicosis: a new disease of horses and humans. Am Rev Soviet Med. 1945;2:238-42.
42. Kaminski E, Stawicki S, Wasowicz E. Volatile flavor compounds produced by molds of Aspergillus, Pennicillium, and Fungi imperfecti. Appl Microbiol. 1974;27:1001-1004.
43. Pohland AE. Mycotoxins in review. Food Addit Contam. 1993;10:17-28.
44. Forgacs J, Carll WT. Mycotoxicoses, Adv Vet Sci. 1962;7:273-382.
45. Ciegler A, Bennett JW. Mycotoxins and mycotoxicoses. BioScience. 1980;30:512-515.
46. Hudler GW. Magical Mushrooms, Mischievous Molds. Princeton, NJ: Princeton University Press; 1998.
47. Emanuel DA, Wenzel FJ, Lawton BR, Pulmonary mycotoxicosis. Chest, 1975;67:293-297.
48. Di Paolo N, Guamieri A, Garosi G, Sacchi G, Mangiarotti AM, Di Paolo M. Inhaled mycotoxins lead to acute renal failure, Nephrol Dial Transplant. 1994; 9(Suppl 4):116-120.
49. National Institute for Occupational Safety and Health (NIOSH). Preventing organic dust toxic syndrome. 1994 Apr.
50. Pratt DS, May JJ. Feed-associated respiratory illness in farmers. Arch Environ Health. 1984;39:43-48.
51. Brinton WT, Vastbinder EE, Greene JW, Marx JJ Jr, Hutcheson RH, Schaffner W. An outbreak of organic dust toxic syndrome in a college fraternity. JAMA. 1987:258:1210-1212.
52. May JJ, Pratt DS, Stallones L, et al. A study of silo unloading: the work environment and its physiologic effects. Am J Ind Med. 1986;10:318.
53. Lacey J, Crook B. Fungal and actinomycete spores as pollutants of the workplace and occupational allergens. Ann Occup Hyg. 1988;32:515-533.
54. Malmberg P, Rask-Andersen A, Rosenhall L. Exposure to microorganisms associated with allergic alveolitis and febrile reactions to mold dust in farmers. Chest. 1993;103:1202-1209.
55. Croft WA, Jarvis BB, Yatawara CS. Airborne outbreak of trichothecene toxicosis. Atmospheric Environ. 1986;20:549-552.
56. Johanning E, Morey PR, Jarvis BB. Clinical-epidemiological investigation of health effects caused by Stachybotrys atra building contamination. Proceedings of Indoor Air '93: Health effects 1993;1:225-230.
57. Johanning E, Biagini R, Hull D, Morey P, Jarvis B, Landsbergis P. Health and immunology study following exposure to toxigenic fungi (Stachybotrys chartarum) in a water-damaged office environment. Int Arch Occup Environ Health. 1996;68:207-218.
58. Hodgson MJ, Morey P, Leung WY. Building-associated pulmonary disease from exposure to Stachybotrys chartarum and Aspergillus versicolor. J Occup Environ Med. 1998;40:241-249.
59. Jarvis BB. Mycotoxins and indoor air quality. In: Morey PR, Feeley JC, Otten JA, eds. Biological Contaminants in Indoor Environments. Philadelphia: ASTM; 1990:201-214.
60. Flannigan B, Miller JD, Health implications of fungi in indoor environments: an overview. In: Samson RA, et al, eds. Health Implications of Fungi in Indoor Environments. Amsterdam: Elsevier; 1994:3-28.
61. Menzies D, Bourbeau J Building-related illnesses, N Engl J Med. 1997;337:1524-1531.
62. Fung F, Clark R, Williams S. Stachybotrys, a mycotoxin-producing fungus of increasing toxicologic importance, J Toxicol Clin Toxicol. 1998;36:79-86.
63. Robbins CA, Swenson LJ, Nealley ML, Gots RE, Kelman BJ. Health effects of mycotoxins in indoor air: a critical review. Appl Occup Environ Hyg. 2000;15:773-784.
64. Sudakin DL. Stachybotrys chartarum: current knowledge of its role in disease. Med Gen Med. 2000;E11.
65. Page EH, Trout DB. The role of Stachybotrys mycotoxins in buildings related illness. Am Ind Hyg Assoc J. 2001;62: 644-648.
66. Terr AI. Stachybotrys: relevance to human disease. Ann Allergy Asthma Immunol. 2001;87:57-63.
67. Burge HA. Fungi: toxic killers or unavoidable nuisances? Ann Allergy Asthma Immunol. 2001;87:52-56.
68. Centers for Disease Control and Prevention (CDC). Acute pulmonary hemorrhage/hemosiderosis among infants Cleveland, January 1993-November 1994. MMWR. 1994;43:881-883.
69. Centers for Disease Control and Prevention (CDC). Update: pulmonary hemorrhage/hemosiderosis among infants Cleveland, Ohio, 1993-1996. MMWR. 1997;46:33-35.
70. Montaña E, Etzel RA, Allan T, Horgan TE, Dearborn DG. Environmental risk factors associated with pediatric idiopathic pulmonary hemorrhage and hemosiderosis in a Cleveland community. Pediatrics. 1997;99:e5.
71. Etzel RA, Montana E, Sorenson WG. Acute pulmonary hemorrhage in infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med. 1998;152:757-762.
72. Centers for Disease Control and Prevention (CDC). Availability of case definition for acute idiopathic pulmonary hemorrhage in infants. MMWR. 2001;50:494-495.
73. Centers for Disease Control and Prevention (CDC). Update: pulmonary hemorrhage/hemosiderosis among infants Cleveland, Ohio, 1993-1996. MMWR. 2000;49:180-184.
74. Creasia DA, Thurman JD, Jones LJ III. Acute inhalation toxicity of T-2 mycotoxin in mice. Fundam Appl Toxicol. 1987;8:230-235.
75. Creasia DA, Thurman JD, Wannemacher RW Jr, Bunner DL. Acute inhalation toxicity of T-2 mycotoxin in the rat and guinea pig. Fundam Appl Toxicol. 1990;14:54-59.
76. Rao CY, Brain JD, Burge HA. Reduction of pulmonary toxicity of Stachybotrys chartarum spores by methanol extraction of mycotoxins. Appl Environ Microbiol. 2000;66:2817-2821.
77. Rao CY, Burge HA, Brain JD. The time course of responses to intratracheally instilled toxic Stachybotrys chartarum spores in rats. Mycopathologia, 2000;149:27-34.
78. EPA Office of Research and Development. Volume I: General Factors. Exposure Factors Handbook, Washington, DC: US Environmental Protection Agency; 1997 Aug.
79. Nikulin M, Reijula K, Jarvis BB, Veijalainen P, Hintikka EL. Effects of intranasal exposure to spores of Stachybotrys atra in mice. Fundam Appl Toxicol. 1997;35:182-188.
80. Shelton BG, Kirkland KH, Flanders WD, Morris GK. Profiles of airborne fungi in buildings and outdoor environments in the United States. Appl Environ Microbiol. 2002;68:1743-1753.
81. Macher J. Bioaerosols: Assessment and Control. Cincinnati, OH: American Conference of Governmental Industrial Hygienists; 1999.
82. American Industrial Hygiene Association. Report of Microbial Growth Task Force. Fairfax, VA: AIHA Press; 2001.
83. EPA Office of Air and Radiation, Indoor Air Division. Mold Remediation in Schools and Commercial Buildings. Washington DC: US Environmental Protection Agency; March 2001.